Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Cosentyx, Lumicef Get Orphan Status for Add’l Indications
December 11, 2019
- “Third Price Revision” Eyed for Expansion of Comparator PMP Deduction Rule
December 11, 2019
- Metformin Manufacturers Ordered to Test for Potential Carcinogen Contamination
December 10, 2019
- Chuikyo Pushes Up-to-5-Band Plan to Address Unreasonable Generic Price Rises, Prods Industry Reorganization
December 9, 2019
- US, European Trade Groups Oppose Tighter Re-Pricing Rules
December 9, 2019
- Pharma Industry Might Accept Comparator PMP Deduction If No Eligible Use Added in 6 Years
December 9, 2019
- Big 4 Wholesalers Faced Wrath of FTC for Allocating Priority Drug Categories before Bidding
December 6, 2019
- Govt Should Focus on Reducing People’s Burdens in 2020 Reimbursement Fee Revision: Aso
December 6, 2019
- Amended PMD Law Promulgated, 3-Step Enforcement to Begin Next Year
December 5, 2019
- Minutes Released for PAFSC's Aug. 29 Meeting, but Most of Discussion on Ono’s Cachexia Drug Undisclosed
December 5, 2019
- Average NHI-Market Price Gap at 8.0%, Suspected Bid-Rigging Data Excluded: Chuikyo
December 4, 2019
- Scandal-Hit JPWA Likely to Pass on Chuikyo’s Industry Hearing on Dec. 6
December 4, 2019
- MHLW Orders Label Revisions for 4 Drugs including Tecentriq
December 4, 2019
- Average NHI-Market Price Gap at “Around 8%”, MHLW Reveals to LDP Bigwigs; Total Savings Undisclosed
December 3, 2019
- Ryukaikon’s Dec. 9 Meeting Likely to Be Put Off in Wake of Bid-Rigging Scandal
December 3, 2019
- Causal Link between Eisai’s Epilepsy Drug and Trial Death Can’t Be Ruled Out: MHLW
December 2, 2019
- MHLW Panel OKs Eisai’s Insomnia Med, Fycompa’s Monotherapy and More
December 2, 2019
- Use of Antibiotics in Japan Down 10.6% in 2018 vs. 2013: MHLW
December 2, 2019
- Komeito Calls for System to Reward Useful New Indications
November 29, 2019
- Japan Pharma Industry Chief Raises Alarm over Comparator PMP Deduction Proposal: LDP Study Group
November 29, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…